Tianmu Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 504.259 million yuan, a year-on-year decrease of 8.88%; net profit to mother was 1.8038 million yuan, a year-on-year decrease of 54.46%. The first three quarters of 2026 achieved operating income of 150 million yuan, a year-on-year decrease of 5.76%; net profit to mother was 8.106 million yuan, a year-on-year decrease of 42.93%; net profit after deducting non-return to mother was 1.844,400 yuan, a year-on-year decrease of 83.05%. The company's compound fresh bamboo extract has resumed production. This product is the company's focus on cultivating OTC varieties. The controlling shareholder plans to publicly solicit and transfer 20% of the company's shares, which may result in changes in the controlling shareholder and actual controller, and approval from the competent authority is still required.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.